These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 26075238)

  • 21. Biosimilars lining up to compete with Herceptin--opportunity knocks.
    Nelson KM; Gallagher PC
    Expert Opin Ther Pat; 2014 Nov; 24(11):1149-53. PubMed ID: 25307085
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improving the power to establish clinical similarity in a Phase 3 efficacy trial by incorporating prior evidence of analytical and pharmacokinetic similarity.
    Zeng D; Pan J; Hu K; Chi E; Lin DY
    J Biopharm Stat; 2018; 28(2):320-332. PubMed ID: 29173074
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Challenges of developing and validating immunogenicity assays to support comparability studies for biosimilar drug development.
    Cai XY; Thomas J; Cullen C; Gouty D
    Bioanalysis; 2012 Sep; 4(17):2169-77. PubMed ID: 23013399
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Scientific and statistical considerations in evaluating the analytical similarity of ABP 501 to adalimumab.
    Sivendran R; Ramírez J; Ramchandani M; Liu J
    Immunotherapy; 2018 Aug; 10(11):1011-1021. PubMed ID: 30071739
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Target-directed development and preclinical characterization of the proposed biosimilar rituximab GP2013.
    da Silva A; Kronthaler U; Koppenburg V; Fink M; Meyer I; Papandrikopoulou A; Hofmann M; Stangler T; Visser J
    Leuk Lymphoma; 2014 Jul; 55(7):1609-17. PubMed ID: 24024472
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biosimilar medicines - Review.
    Dos Reis C; Teixo R; Mendes F; Cruz RS
    Int J Risk Saf Med; 2016 Mar; 28(1):45-60. PubMed ID: 27176756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of structural and functional similarity of biosimilar products: Rituximab as a case study.
    Nupur N; Chhabra N; Dash R; Rathore AS
    MAbs; 2018 Jan; 10(1):143-158. PubMed ID: 29200314
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.
    Braun J; Kudrin A
    Immunotherapy; 2015; 7(2):73-87. PubMed ID: 25713985
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessing analytical comparability of biosimilars: GCSF as a case study.
    Nupur N; Singh SK; Narula G; Rathore AS
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Oct; 1032():165-171. PubMed ID: 27289250
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biosimilar monoclonal antibodies: preclinical and clinical development aspects.
    Gonçalves J; Araújo F; Cutolo M; Fonseca JE
    Clin Exp Rheumatol; 2016; 34(4):698-705. PubMed ID: 27383278
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recommendations for the Development and Validation of Immunogenicity Assays in Support of Biosimilar Programs.
    Civoli F; Kasinath A; Cai XY; Wadhwa M; Exley A; Oldfield P; Alvandkouhi S; Schaffar G; Chappell J; Bowsher R; Devanarayan V; Marini J; Rebarchak S; Anderson M; Koppenburg V; Lester T
    AAPS J; 2019 Dec; 22(1):7. PubMed ID: 31792633
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analytical similarity assessment of rituximab biosimilar CT-P10 to reference medicinal product.
    Lee KH; Lee J; Bae JS; Kim YJ; Kang HA; Kim SH; Lee SJ; Lim KJ; Lee JW; Jung SK; Chang SJ
    MAbs; 2018 Apr; 10(3):380-396. PubMed ID: 29469653
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Considerations in the early development of biosimilar products.
    Li EC; Abbas R; Jacobs IA; Yin D
    Drug Discov Today; 2015 May; 20 Suppl 2():1-9. PubMed ID: 25572407
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Milestones over the development of SB3, a trastuzumab biosimilar.
    Pivot X; Bondarenko I; Petit T; Curtit E
    Future Oncol; 2018 Nov; 14(27):2795-2803. PubMed ID: 29927335
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Challenges in the implementation of trastuzumab biosimilars: an expert panel's recommendations.
    Pivot X; Aulagner G; Blay JY; Fumoleau P; Kaliski A; Sarkozy F; Limat S
    Anticancer Drugs; 2015 Nov; 26(10):1009-16. PubMed ID: 26352219
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Physicochemical and functional assessments demonstrating analytical similarity between rituximab biosimilar HLX01 and the MabThera®.
    Xu Y; Xie L; Zhang E; Gao W; Wang L; Cao Y; Xie MH; Jiang W; Liu S
    MAbs; 2019 Apr; 11(3):606-620. PubMed ID: 30794092
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trastuzumab biosimilar in metastatic breast cancer: Evaluating equivalence with originator using network meta-analysis
.
    Mengato D; Chiumente M; Messori A
    Int J Clin Pharmacol Ther; 2019 Mar; 57(3):160-162. PubMed ID: 30574866
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical development and trial design of biosimilar products: a Japanese perspective.
    Nagasaki M; Ando Y
    J Biopharm Stat; 2014; 24(6):1165-72. PubMed ID: 25033370
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New Alternatives for Autoimmune Disease Treatments: Physicochemical and Clinical Comparability of Biosimilar Etanercept.
    Miranda-Hernández MP; López-Morales CA; Perdomo-Abúndez FC; Salazar-Flores RD; Ramírez-Ibanez ND; Pérez NO; Molina-Pérez A; Revilla-Beltri J; Flores-Ortiz LF; Medina-Rivero E
    J Immunol Res; 2016; 2016():9697080. PubMed ID: 27382576
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomised clinical endpoint studies for trastuzumab biosimilars: a systematic review.
    Coory M; Thornton K
    Breast Cancer Res Treat; 2019 Jul; 176(1):17-25. PubMed ID: 30980209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.